126 related articles for article (PubMed ID: 1908390)
1. Sarcoma-180 cells and human colorectal tumor cells under in vitro hypoxic conditions are more sensitive to mitomycin C and carboquone.
Kusumoto T; Maehara Y; Sakaguchi Y; Kohnoe S; Emi Y; Sugimachi K
Eur J Surg Oncol; 1991 Aug; 17(4):358-63. PubMed ID: 1908390
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia enhances the lethality of mitomycin C and carboquone against human malignant tumor cells in vitro.
Kusumoto T; Maehara Y; Sakaguchi Y; Saku M; Sugimachi K
Eur Surg Res; 1989; 21(3-4):224-31. PubMed ID: 2509206
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia and acidity increase the cytotoxicity of mitomycin C and carboquone to human tumor cells in vitro.
Kohnoe S; Emi Y; Takahashi I; Yoshida M; Maehara Y; Sugimachi K
Anticancer Res; 1991; 11(4):1401-4. PubMed ID: 1746896
[TBL] [Abstract][Full Text] [Related]
4. Tumor tissue is more sensitive to mitomycin C, carboquone, and aclacinomycin A than is adjacent normal tissue in vitro.
Maehara Y; Kusumoto H; Kusumoto T; Anai H; Sugimachi K
J Surg Oncol; 1989 Jan; 40(1):4-7. PubMed ID: 2909804
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of mitomycin C and carboquone combined with hyperthermia against hypoxic tumor cells in vitro.
Sakaguchi Y; Kohnoe S; Emi Y; Maehara Y; Kusumoto T; Sugimachi K
Oncology; 1992; 49(3):227-32. PubMed ID: 1495751
[TBL] [Abstract][Full Text] [Related]
6. [The sensitivity of 1,000 human tumors to antitumor drugs using the succinate dehydrogenase inhibition (SDI) test].
Miyamoto K; Fukuchi K
Rinsho Byori; 1990 Nov; 38(11):1273-8. PubMed ID: 2273570
[TBL] [Abstract][Full Text] [Related]
7. The difference in chemosensitivity to antineoplastic agents of human hepatocellular carcinoma cells under normo-oxygenated or hypoxic conditions.
Yamagata M; Kanematsu T; Matsumata T; Utsunomiya T; Ikeda Y; Sugimachi K
Eur J Surg Oncol; 1992 Aug; 18(4):379-82. PubMed ID: 1325926
[TBL] [Abstract][Full Text] [Related]
8. Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma.
Maehara Y; Anai H; Kusumoto H; Sugimachi K
Eur J Surg Oncol; 1987 Jun; 13(3):203-6. PubMed ID: 3036603
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytes anticancer chemosensitivity testing in vitro--an approach to predict immunosuppressive effect of anticancer agents.
Nio Y; Imai S; Shiraishi T; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 Jul; 29(3):141-5. PubMed ID: 2517429
[TBL] [Abstract][Full Text] [Related]
10. Anticancer chemosensitivity and growth rate of freshly separated human colorectal cancer cells assessed by in vitro DNA synthesis inhibition assay.
Kawabata K; Nio Y; Imamura M; Fukumoto M
Anticancer Res; 1998; 18(3A):1633-40. PubMed ID: 9673382
[TBL] [Abstract][Full Text] [Related]
11. Colorectal carcinoma in vitro is more sensitive to 1-hexylcarbamoyl-5-fluorouracil compared with six other antitumor drugs: carboquone, Adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil.
Maehara Y; Anai H; Kusumoto H; Kusumoto T; Sugimachi K
Dis Colon Rectum; 1988 Jan; 31(1):62-7. PubMed ID: 3130239
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity testing of human lung cancer tissues using the succinate dehydrogenase inhibition test.
Mitsudomi T; Kaneko S; Tateishi M; Yano T; Ishida T; Kohnoe S; Maehara Y; Sugimachi K
Anticancer Res; 1990; 10(4):987-90. PubMed ID: 2382998
[TBL] [Abstract][Full Text] [Related]
13. Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay.
Nio Y; Tamura K; Kan N; Inamoto T; Ohgaki K; Kodama H
Anticancer Res; 2000; 20(2B):1237-44. PubMed ID: 10810427
[TBL] [Abstract][Full Text] [Related]
14. Lung adenocarcinoma is more sensitive than gastric adenocarcinoma to anticancer drugs in vitro.
Kohnoe S; Moriguchi S; Emi Y; Sakaguchi Y; Maehara Y; Ishida T; Mitsudomi T; Sugimachi K
Eur J Surg Oncol; 1991 Feb; 17(1):47-50. PubMed ID: 1995357
[TBL] [Abstract][Full Text] [Related]
15. Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues.
Takeuchi H; Baba H; Inutsuka S; Takahashi I; Kusumoto H; Maehara Y; Sugimachi K
Anticancer Res; 1994; 14(1A):169-71. PubMed ID: 8166444
[TBL] [Abstract][Full Text] [Related]
16. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells.
Willson JK; Long BH; Chakrabarty S; Brattain DE; Brattain MG
Cancer Res; 1985 Nov; 45(11 Pt 1):5281-6. PubMed ID: 3931904
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of mitomycin C in cultured human bladder tumors.
Schmittgen TD; Wientjes MG; Badalament RA; Au JL
Cancer Res; 1991 Aug; 51(15):3849-56. PubMed ID: 1906778
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
Fracasso PM; Sartorelli AC
Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
[TBL] [Abstract][Full Text] [Related]
19. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer.
Kusumoto H; Maehara Y; Kusumoto T; Anai H; Akazawa K; Sugimachi K
Eur J Surg Oncol; 1988 Dec; 14(6):685-9. PubMed ID: 3192005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
